Skip to search formSkip to main content

AMI 25

Known as: AMI-25, AMI25 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1998
Review
1998
Abstract. A variety of parenterally administered iron oxides have been developed for contrast-enhanced MRI of the liver. Two… Expand
  • table 1
Is this relevant?
Highly Cited
1996
Highly Cited
1996
PURPOSE To assess AMI-25- versus gadolinium-enhanced magnetic resonance (MR) imaging in the differential diagnosis of liver… Expand
Is this relevant?
1994
1994
PURPOSE To evaluate the ability of magnetic resonance (MR) imaging enhanced with AMI-25 to depict and characterize hepatic tumors… Expand
Is this relevant?
Highly Cited
1990
Highly Cited
1990
An ultrasmall superparamagnetic iron oxide (USPIO) preparation was developed that is small enough to migrate across the capillary… Expand
Is this relevant?
1990
1990
We have applied a superparamagnetic iron oxide formulation (AMI-25, Advanced Magnetics, Inc., Cambridge, MA) to image the… Expand
Is this relevant?
1990
1990
A new contrast agent for magnetic resonance (MR) imaging, directed to asialoglycoprotein (ASG) receptors on hepatocytes, was used… Expand
Is this relevant?
1990
1990
Previous studies of AMI-25, a particulate iron oxide magnetic resonance contrast agent, imaged liver tumors 1 or more hours after… Expand
Is this relevant?
Highly Cited
1989
Highly Cited
1989
The pharmacokinetics (distribution, metabolism, bioavailability, excretion) and toxicity (acute and subacute toxicity… Expand
Is this relevant?
1989
1989
This study was designed to evaluate superparamagnetic iron oxide (AMI-25) as a contrast agent for MR to distinguish normal… Expand
Is this relevant?
1988
1988
Superparamagnetic iron oxide (AMI-25), a reticuloendothelial cell-specific contrast agent for magnetic resonance (MR) imaging… Expand
Is this relevant?